Abstract

The etiologic role of Epstein-Barr virus (EBV) for B lymphomagenesis has been postulated from epidemiologic and in vitro studies. There is now a substantial body of evidence linking EBV to African Burkitt’s lymphoma, which is a B-cell lymphoma (Klein 1985). An association between EBV and human malignancies, including Hodgkin’s disease (Weiss et al. 1987) and non-Hodgkin’s lymphomas of either B- or T-cell immunophenotypes (Hochberg et al. 1983; Hamilton-Dutoit et al. 1992), has been reported. EBV-positive rate in immunocompetent patients with nodal lymphomas is less than 10% in B-cell and approximately 50% in T-cell lymphoma (Aozasa et al. 1998). The criteria for defining cases as EBV-positive includes (1) presence of EBV genome by Polymerase chain reaction (PCR), and (2) positive signals for EBV in large tumor cells by DNA or RNA in situ hybridization (ISH) using EBV-encoded small nuclear early region-1 (EBER1) probe. Among extranodal lymphomas, nasal natural killer (NK)-cell lymphoma, pyothorax-associated lymphoma (PAL), and adrenal lymphoma are EBV-associated; the EBV-positive rate is over 90% in the nasal lymphoma and PAL and approximately 50% in the adrenal lymphoma.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.